Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression

Oncogene

Volumn 33, Issue 36, 2014, Pages 4474-4484

  Bengsch, F ^a   Buck, A ^a   Gunther S C ^a   Seiz, J R ^a   Tacke, M ^a   Pfeifer, D ^b   Von Elverfeldt, D ^b   Sevenich, L ^a,e   Hillebrand, L E ^a   Kern, U ^a   Sameni, M ^c   Peters, C ^a   Sloane, B F ^c,d   Reinheckel, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

breast cancer; CTSB; invasion; macrophages

Indexed keywords

CATHEPSIN B; CTSB PROTEIN, HUMAN; DOXYCYCLINE; SCLEROPROTEIN; VIRUS T ANTIGEN;

ANIMAL; ARTICLE; BREAST TUMOR; DISEASE COURSE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MACROPHAGE; METABOLISM; MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; STROMA CELL; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSIN B; DISEASE PROGRESSION; DOXYCYCLINE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; STROMAL CELLS;

EID: 84884654881     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.395     Document Type: Article

References (55)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-550.
3. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2012; 32: 303-315.
4. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol 2011; 21: 228-237.
5. Rawlings ND, Morton FR, Kok CY, Kong JBarrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2008; 36: D320-D325.
6. Tu C, Ortega-Cava CF, Chen G, Fernandes ND, Cavallo-Medved D, Sloane BF et al. Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res 2008; 68: 9147-9156.
7. Jane DT, Morvay L, Dasilva L, Cavallo-Medved D, Sloane BF, Dufresne MJ. Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH. Biol Chem 2006; 387: 223-234.
8. Harbeck N, Alt U, Berger U, Kruger A, Thomssen C, Janicke F et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 2757-2764.
9. Nouh MA, Mohamed MM, El-Shinawi M, Shaalan MA, Cavallo-Medved D, Khaled HM et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011; 9: 1.
10. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004; 385: 1017-1027.
11. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006; 66: 5242-5250.
12. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010; 24: 241-255.
13. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012; 33: 119-126.
14. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
15. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
16. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
17. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-630.
18. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007; 67: 2649-2656.
19. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543-556.
20. Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J et al. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 2012; 61: 877-884.
21. Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S et al. Synergistic anti-tumor effects of cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA 2010; 107: 2497-2502.
22. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23: 8486-8496.
23. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23: 4681-4689.
24. Malla RR, Gopinath S, Gondi CS, Alapati K, Dinh DH, Gujrati M et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 2011; 18: 419-434.
25. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004; 5: 443-453.
26. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-2479.
27. Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012; 72: 1199-1209.
28. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 2007; 67: 7378-7385.
29. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I et al. Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 1992; 30: 69-74.
30. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 764-775.
31. Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E et al. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell 2012; 45: 764-776.
32. Sevenich L, Werner F, Gajda M, Schurigt U, Sieber C, Muller S et al. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma- middle-T-induced breast cancer in mice. Oncogene 2011; 30: 54-64.
33. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148: 3-15.
34. Friedl P, Locker J, Sahai E, Segall J. Classifying collective cancer cell invasion. Nat Cell Biol 2012; 14: 777-783.
35. Keppler DSloane BF. Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 1996; 49: 94-105.
36. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol 2011; 6: 594-602.
37. Sinha AA, Gleason DF, Deleon OF, Wilson MJ, Sloane BF. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec 1993; 235: 233-240.
38. Maciewicz RA, Etherington DJ. A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J 1988; 256: 433-440.
39. Buck MR, Karustis DG, Day NA, Honn KVSloane BF. Degradation of extracellularmatrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992; 282(Pt 1): 273-278.
40. Heroon Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorsji I. Macrophage Cathepsin K promotes prostate tumor progression in bone. Oncogene 2012; 32: 1580-1593.
41. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, Kirschmann DA. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 2005; 65: 11429-11436.
42. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005; 118: 1493-1503.
43. Victor BC, Sloane BF. Cysteine cathepsin non-inhibitory binding partners: modulating intracellular trafficking and function. Biol Chem 2007; 388: 1131-1140.
44. Brisson L, Reshkin SJ, Gore J, Roger S. pH regulators in invadosomal functioning: Proton delivery for matrix tasting. Eur J Cell Biol 2012; 91: 847-860.
45. Cesen MH, Pegan K, Spes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 2012; 318: 1245-1251.
46. Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene 2013; 32: 1995-2004.
47. Vasiljeva O, Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumour invasion. Biochimie 2008; 90: 380-386.
48. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65: 2993-2995.
49. Houseweart MK, Pennacchio LA, Vilaythong A, Peters C, Noebels JL, Myers RM. Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J Neurobiol 2003; 56: 315-327.
50. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-961.
51. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
52. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 2001; 17: 509-519.
53. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284.
54. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR et al. Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis 2009; 26: 299-309.
55. Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem 2008; 389: 1067-1074.